Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.
about
Biomarkers in vasculitisHaptoglobin expression and activity during coronary collateralization.Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells.Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.Thrombosis in vasculitis: from pathogenesis to treatment.A novel pathway to the manifestations of metabolic syndrome.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study.Role of A2B adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells.Effect of tocopherol supplementation during last trimester of pregnancy on mRNA abundances of interleukins and angiogenesis in ovine placenta and uterusInflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis.Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.Cardiac Stem Cell Secretome Protects Cardiomyocytes from Hypoxic Injury Partly via Monocyte Chemotactic Protein-1-Dependent Mechanism.Pathophysiology of vascular remodeling in hypertensionGiant cell arteritis and angiogenesis: a review.Current understanding and management of giant cell arteritis and polymyalgia rheumatica.Delays in recognition and management of giant cell arteritis: results from a retrospective audit.Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.Immunotherapeutic implication of IL-6 blockade.Clinical features of polymyalgia rheumatica and giant cell arteritis.Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.Visual loss and other cranial ischaemic complications in giant cell arteritis.Gelatinase expression and proteolytic activity in giant-cell arteritis.Adenosine A2B receptors on cardiac stem cell antigen (Sca)-1-positive stromal cells play a protective role in myocardial infarction.Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow.Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis.Functional role of wogonin in anti-angiogenesis.Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells.Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.TLR4 stimulation by LPS enhances angiogenesis in a co-culture system consisting of primary human osteoblasts and outgrowth endothelial cells.Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings.Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis.Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemiaAssociation of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes
P2860
Q26825345-139CCA53-96A0-4E8B-9B35-1EF3D54A9296Q33209077-BFB172A0-72D6-4FA8-BA9F-FFCEDEE80CC1Q33919411-F1C19E99-402B-4403-89A9-0717D3E174ADQ34377832-E0CE6E79-89BD-4D69-BF59-E362A374C5EDQ34540533-798C8688-EA60-4896-B42A-C1F80DD63AB0Q35440601-3FD904AD-FC93-468E-9914-9BFD26E3949BQ35674454-246309E8-E0DC-41CD-94BC-909A09D678B7Q35724900-5A039648-3E18-40B5-A473-36E4E6FC1098Q35931060-E4C2A0F0-0C16-43C1-BECD-E800127D2D43Q35996708-53B7F4F1-8F33-49FC-899A-35AD62E5334BQ36099171-10E1DE6E-C49F-40B7-B97E-23090C59926CQ36747926-5F829DE3-163D-45CA-BD7F-BF2CCE94B5F0Q36843077-A0C996F8-F7F9-4822-8D8E-77FDD1937AF9Q37050454-3F479ABD-177C-4FB9-8C02-6FE6483250E4Q37077772-A60806BA-191B-4B3A-8B81-986CBD82F6A2Q37479388-5294D5C6-3A45-4E64-B747-039551B39CEBQ37803414-D899EAD9-FBE4-4695-9BE8-E993560BA892Q37810491-27C475F0-A38B-4B1A-833F-28DE0D216ADCQ37854935-692BA0DD-66FF-41BA-AAD7-DC44B9B17999Q37965754-296031A2-A16D-4E4A-805F-6A45B94515DFQ38028863-23DDFED8-BAD3-4F76-B1F7-303A906B31AFQ38653449-60C479BF-0E57-4108-93AA-091E7C3536D4Q38787301-B901A33B-7288-4BAC-A10C-3409560CBB5EQ39416333-05569C33-BF5A-498B-85CA-BE64B48100C0Q41348284-2854F962-E3E3-4AB5-9A25-E523CF24771DQ41976027-63E8F2FA-B068-447F-99E1-4CEE16DAF556Q43035849-1097C2D2-220B-42A8-8F53-D5D031BD6617Q44902169-7994B631-30D0-4E4C-AD3F-7F89BCBAEC6CQ45034871-3C5627AE-B946-468D-B133-3F809C127EC1Q45756646-3FD5A55B-E878-4CA0-B4E1-FE6FBD5DE2B3Q45964348-4BD13E9D-1AA4-442C-AA6F-148734A10FEAQ47104190-C0B99E03-C196-400F-BBB3-46DFA21510F4Q48592090-0DCA49D3-FD4D-4A26-B5C5-E516E10A1A86Q51033475-6A0E0FCE-536C-4A77-B0C0-E95F332288DBQ51836448-CB2BC6C6-C324-45E2-8D83-1492AE087A58Q52893205-2B217C4B-C623-4B75-98DB-1A46643B2325Q52983767-69AC7B2A-3770-4E3E-B1A9-07C01E8B6D35Q53118262-F6C6AEBA-E8B3-4192-9859-0E6FC7ED4062Q56942323-CD0707A0-8107-427B-BFF3-2484174A45F2Q57279273-34F42AA6-2E4C-4278-BB6A-22267B04FDCB
P2860
Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Elevated production of interle ...... otential protective mechanism.
@en
Elevated production of interle ...... otential protective mechanism.
@nl
type
label
Elevated production of interle ...... otential protective mechanism.
@en
Elevated production of interle ...... otential protective mechanism.
@nl
prefLabel
Elevated production of interle ...... otential protective mechanism.
@en
Elevated production of interle ...... otential protective mechanism.
@nl
P2093
P1433
P1476
Elevated production of interle ...... potential protective mechanism
@en
P2093
Alvaro Urbano-Márquez
Ana García-Martínez
Carme Vilardell
Hynda K Kleinman
Josep M Grau
Maria C Cid
Marta Segarra
María-José Esteban
Montse Sánchez
P304
P356
10.1161/01.CIR.0000066907.83923.32
P407
P577
2003-05-12T00:00:00Z